Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Type 1 diabetes: laboratory follow-up in adults and children

Endocrinology and metabolism · Known disease · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: In adults, the prevalence of type 1 diabetes is estimated at between 0.3 and 0.5% (about 10% of diabetes); in those under 15, the incidence is 18 per 100 000 (2013-2015) [1].

At diagnosis, once blood glucose is stable (child and adult)

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Adult: HbA1c every 3 to 6 months

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Adult: annual tests

Laboratory tests

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Child and adolescent: follow-up shared with the paediatric team

Every 3 months

Once a year

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (17)
  1. Santé publique France. Épidémiologie du diabète de type 1 et de ses complications. Publié le 1er juin 2018, mis à jour le 20 novembre 2019.
  2. Fröhlich-Reiterer E, Elbarbary NS, Simmons K, Buckingham B, Humayun KN, Johannsen J, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Other complications and associated conditions in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2022;23(8):1451-1467.
  3. Haute Autorité de santé. Guide affection de longue durée (ALD 8) : diabète de type 1 de l'adulte. Juillet 2007.
  4. Haute Autorité de santé. Guide affection de longue durée (ALD 8) : diabète de type 1 de l'enfant et de l'adolescent. Juillet 2007.
  5. American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S297-S320.
  6. American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S61-S88.
  7. National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE guideline NG18 (recommandations 1.2.x sur l'HbA1c et 1.2.119 à 1.2.121).
  8. National Institute for Health and Care Excellence. Coeliac disease: recognition, assessment and management. NICE guideline NG20 (recommandations 1.1 et 1.2).
  9. Bjornstad P, Dart A, Donaghue KC, Dost A, Feldman EL, Tan GS, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes. Pediatr Diabetes. 2022;23(8):1432-1450.
  10. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. NICE guideline NG17 (recommandations 1.6, 1.11, 1.12.2 et 1.14.39).
  11. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
  12. République italienne. Legge 15 settembre 2023, n. 130 : Disposizioni concernenti la definizione di un programma diagnostico per l'individuazione del diabete di tipo 1 e della celiachia nella popolazione pediatrica. Gazzetta Ufficiale n. 226 du 27/09/2023.
  13. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1487 (anticorps anti-TPO), 1208 (TSH), 1828 (anti-transglutaminase IgA), 1577 (HbA1c) et 1576 (protéines glyquées).
  14. American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
  15. Deutsche Diabetes Gesellschaft (DDG). S3-Leitlinie Therapie des Typ-1-Diabetes, 2. Auflage. AWMF-Registernummer 057-013, 2018 (validité indiquée : mai 2018 à mai 2023).
  16. American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
  17. Phelan H, Hanas R, Hofer SE, James S, Landry A, Lee W, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Sick day management in children and adolescents with diabetes. Pediatr Diabetes. 2022;23(7):912-925.